8-K: Acadia Pharmaceuticals: Remlifanserin Shows Promise in Alzheimer's Psychosis Trial

Acadia Pharmaceuticals announced topline results from the Phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis, showing a favorable safety profile and trends supporting continued Phase 3 development.

Summary

• Acadia Pharmaceuticals announced topline results from the Phase 2 portion of the RADIANT clinical trial program for remlifanserin, an investigational drug for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).
• The 60 mg dose of remlifanserin demonstrated a change of -12.6 on the primary endpoint (SAPS-H+D) versus -10.4 for placebo (p=0.0603), narrowly missing statistical significance.
• A key secondary endpoint, Clinical Global Impression Severity (CGI-S-ADP), showed a change of -1.3 for the 60 mg dose versus -0.9 for placebo (p=0.0077 nominal), indicating statistical significance.
• The 30 mg dose showed minimal improvement compared to placebo.
• Remlifanserin exhibited a favorable safety and tolerability profile across both doses, with adverse event rates similar to placebo and no signal of QT prolongation.
• The company plans to continue enrolling its two ongoing Phase 3 studies and will amend the program to remove the 30 mg dosage arm.
• Detailed results will be presented at the CTAD conference from November 16-19, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic development. While the drug narrowly missed its primary endpoint, it showed statistical significance on a key secondary endpoint and a favorable safety profile, supporting continued Phase 3 development.

Positives

• The 60 mg dose of remlifanserin achieved statistical significance on a key secondary endpoint (CGI-S-ADP) with a p-value of 0.0077.
• The drug demonstrated a favorable safety and tolerability profile, with adverse event rates similar to placebo.
• There was no signal of QT prolongation observed.
• The data suggest no negative impact on motor symptoms or cognition.
• No deaths were reported in the remlifanserin treatment arms.
• The results support continuing with Phase 3 development of the 60 mg dose.
• The company plans to present detailed results at the upcoming CTAD conference.

Negatives

• The 60 mg dose narrowly missed the primary endpoint (SAPS-H+D) with a p-value of 0.0603.
• The 30 mg dose showed minimal improvement across endpoints compared to placebo.

Risks

• Risks associated with the discovery, development, and regulation of pharmaceutical products in general.
• Future clinical trials may not support approval of product candidates.
• Future clinical trial results may not be consistent with interim, initial, preliminary, or topline results.
• Dependency on the continued successful commercialization of Nuplazid and Daybue.
• Ability to generate or obtain necessary capital to fund clinical development plans.
• Timing and results of clinical trials.
• Ability to maintain, protect, and enhance intellectual property.
• Ability to remain in compliance with applicable laws and regulations.

Future Outlook

The company plans to continue enrolling its two ongoing Phase 3 studies evaluating remlifanserin in ADP and will implement amendments to the Phase 3 program, including removing the 30 mg dosage arm. Detailed safety and efficacy results will be presented at the CTAD conference.

Management Comments

• "We are pleased that the Phase 2 RADIANT data support continuation of the Phase 3 ADP program, with new insights helping us to refine the program for future regulatory success."
• "These results provide valuable information regarding the efficacy, safety and tolerability of once daily remlifanserin in Alzheimers disease psychosis."
• "We are excited about the potential of remlifanserin in this area of high unmet need, for which there are no currently approved therapies."
• "The Phase 2 RADIANT findings provide encouraging evidence that 60 mg once daily remlifanserin may have the potential to reduce hallucinations and delusions in patients with Alzheimers disease."
• "This patient population has a significant need for an efficacious medication that is well tolerated, convenient to administer, and is compatible with the many concomitant medications commonly used by patients with Alzheimers disease."
• "In particular, avoiding negative impacts on motor symptoms and cognition is encouraging, and such a medicine could be an important treatment option for patients."

Industry Context

StockSavvy.ai notes that Alzheimer's disease psychosis (ADP) is a significant unmet medical need with no FDA-approved therapies. The development of remlifanserin, if successful, could represent a substantial advancement in treating this condition, which affects a considerable portion of Alzheimer's patients and leads to increased caregiver burden and institutionalization.

Stakeholder Impact

• Shareholders: The results may influence investor sentiment and stock valuation, with continued Phase 3 development being a positive indicator, while the missed primary endpoint introduces some uncertainty.
• Patients with Alzheimer's Disease Psychosis: Potential for a new treatment option if remlifanserin is successful in Phase 3 trials, addressing a significant unmet need.
• Caregivers: A successful treatment could alleviate the burden associated with managing psychosis in Alzheimer's patients.
• Healthcare Providers: The availability of a new therapeutic agent could offer an additional tool for managing ADP symptoms.

Next Steps

• Continue enrolling patients in the two ongoing Phase 3 studies for remlifanserin in ADP.
• Implement amendments to the Phase 3 program, including removing the 30 mg dosage arm.
• Present detailed safety and efficacy results from the RADIANT Phase 2 study at the CTAD conference (November 16-19, 2026).
• Investigate remlifanserin in an additional Phase 2 study for Lewy body dementia psychosis.

Key Dates

Recommendation

The filing presents mixed results: while the drug narrowly missed its primary endpoint, it achieved statistical significance on a key secondary endpoint and demonstrated a favorable safety profile. This supports continued Phase 3 development but introduces enough uncertainty to warrant a 'hold' recommendation until further Phase 3 data are available.

Keywords

Alzheimer's Disease Psychosis, Remlifanserin, Clinical Trial, Phase 2, Phase 3, Hallucinations, Delusions, Neurology